144 related articles for article (PubMed ID: 11457836)
1. Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding.
Wang D; Quillan JM; Winans K; Lucas JL; Sadée W
J Biol Chem; 2001 Sep; 276(37):34624-30. PubMed ID: 11457836
[TBL] [Abstract][Full Text] [Related]
2. Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP(3)) in morphine-pretreated cell.
Wang D; Surratt CK; Sadée W
J Neurochem; 2000 Aug; 75(2):763-71. PubMed ID: 10899953
[TBL] [Abstract][Full Text] [Related]
3. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
4. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
[TBL] [Abstract][Full Text] [Related]
5. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
6. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling.
Befort K; Filliol D; Decaillot FM; Gaveriaux-Ruff C; Hoehe MR; Kieffer BL
J Biol Chem; 2001 Feb; 276(5):3130-7. PubMed ID: 11067846
[TBL] [Abstract][Full Text] [Related]
7. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
8. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
9. Calmodulin binding to G protein-coupling domain of opioid receptors.
Wang D; Sadée W; Quillan JM
J Biol Chem; 1999 Jul; 274(31):22081-8. PubMed ID: 10419536
[TBL] [Abstract][Full Text] [Related]
10. Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening.
Brillet K; Kieffer BL; Massotte D
BMC Pharmacol; 2003 Dec; 3():14. PubMed ID: 14641935
[TBL] [Abstract][Full Text] [Related]
11. Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1.
Narayan A; Hunkele A; Xu J; Bassoni DL; Pasternak GW; Pan YX
Cell Mol Neurobiol; 2021 Jul; 41(5):1059-1074. PubMed ID: 33033993
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.
Sally EJ; Xu H; Dersch CM; Hsin LW; Chang LT; Prisinzano TE; Simpson DS; Giuvelis D; Rice KC; Jacobson AE; Cheng K; Bilsky EJ; Rothman RB
Synapse; 2010 Apr; 64(4):280-8. PubMed ID: 19953652
[TBL] [Abstract][Full Text] [Related]
13. The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs.
Fortin JP; Ci L; Schroeder J; Goldstein C; Montefusco MC; Peter I; Reis SE; Huggins GS; Beinborn M; Kopin AS
Mol Pharmacol; 2010 Nov; 78(5):837-45. PubMed ID: 20702761
[TBL] [Abstract][Full Text] [Related]
14. G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity.
Burford NT; Wang D; Sadée W
Biochem J; 2000 Jun; 348 Pt 3(Pt 3):531-7. PubMed ID: 10839983
[TBL] [Abstract][Full Text] [Related]
15. Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling.
Koch T; Kroslak T; Averbeck M; Mayer P; Schröder H; Raulf E; Höllt V
Mol Pharmacol; 2000 Aug; 58(2):328-34. PubMed ID: 10908300
[TBL] [Abstract][Full Text] [Related]
16. Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance.
Sim-Selley LJ; Scoggins KL; Cassidy MP; Smith LA; Dewey WL; Smith FL; Selley DE
Br J Pharmacol; 2007 Aug; 151(8):1324-33. PubMed ID: 17572699
[TBL] [Abstract][Full Text] [Related]
17. mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation.
Belcheva MM; Szùcs M; Wang D; Sadee W; Coscia CJ
J Biol Chem; 2001 Sep; 276(36):33847-53. PubMed ID: 11457825
[TBL] [Abstract][Full Text] [Related]
18. Selective interactions of mu-opioid receptors with pertussis toxin-sensitive G proteins: involvement of the third intracellular loop and the c-terminal tail in coupling.
Georgoussi Z; Merkouris M; Mullaney I; Megaritis G; Carr C; Zioudrou C; Milligan G
Biochim Biophys Acta; 1997 Dec; 1359(3):263-74. PubMed ID: 9434132
[TBL] [Abstract][Full Text] [Related]
19. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside diphosphate kinase associated with membranes modulates mu-opioid receptor-mediated [35S]GTPgammaS binding and agonist binding to mu-opioid receptor.
Zhang D; Li JG; Chen C; Liu-Chen LY
Eur J Pharmacol; 1999 Jul; 377(2-3):223-31. PubMed ID: 10456435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
